Naperville R&D Tax Credit Explained for Businesses

R&D Tax Credits for Naperville, Illinois Businesses

Naperville, Illinois, is known for its strong presence in healthcare, education, technology, and retail. Top companies in the city include Edward Hospital, a major healthcare provider; North Central College, a key educational institution; Nalco Water, a prominent technology company; Walmart, a global retail giant; and Amazon, a global logistics and e-commerce company. The R&D Tax Credit can help these industries reduce tax liabilities, encourage innovation, and enhance business performance. By utilizing the R&D Tax Credit, companies can reinvest savings into advanced research driving growth and competitiveness in Naperville’s economy.

Find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 318 West Adams Street, Chicago, Illinois is less than 35 miles away from Naperville and provides R&D tax credit consulting and advisory services to Naperville and the surrounding areas such as: Chicago, Aurora, Joliet, Rockford and Elgin.

If you have any questions or need further assistance, please call or email our local Illinois Partner on (312) 380-0467.
Feel free to book a quick teleconference with one of our Illinois R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Naperville, Illinois Patent of the Year – 2024/2025

OWP Pharmaceuticals Inc. has been awarded the 2024/2025 Patent of the Year for its groundbreaking advancement in neurological treatment delivery. Their invention, detailed in U.S. Patent No. 11872309, titled ‘Topiramate oral liquid suspension and use thereof’, introduces an oral liquid suspension of topiramate, offering a novel administration method for patients with epilepsy and bipolar disorder.

This formulation addresses a significant gap in treatment options for individuals who struggle with swallowing pills, such as children and older adults. The liquid suspension ensures precise dosing and improved patient compliance, which is crucial for managing chronic neurological conditions.

Topiramate, traditionally available in tablet form, is widely used to treat partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. It’s also prescribed for bipolar disorder to delay the occurrence of mood episodes. The new liquid form maintains the drug’s efficacy while enhancing its accessibility.

The patent outlines a suspension containing 25 mg/mL of topiramate, combined with ingredients like glycerin, propylene glycol, and various stabilizers to ensure consistency and shelf stability. This innovation reflects OWP Pharmaceuticals’ commitment to developing patient-centric solutions in neuroscience.

By transforming a well-established medication into a more versatile form, OWP Pharmaceuticals is setting a precedent in pharmaceutical innovation, potentially improving treatment adherence and outcomes for patients worldwide.